Literature DB >> 20305828

Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS.

A Mario Marcondes1, Aravind Ramakrishnan, H Joachim Deeg.   

Abstract

There is growing evidence for a role of the hemopoietic microenvironment in the pathophysiology of myelodysplastic syndromes (MDS). Effects of various cytokines on the marrow microenvironment of patients with MDS have been studied. Autoimmunity, i.e. a reaction of autologous T lymphocytes against components of the marrow is also operative in a proportion of patients with MDS. The negative feed-back loop that controls tumor necrosis factor (TNF)α levels in healthy individuals is apparently disrupted in MDS due to auto-amplification signals involving TNFα and interleukin (IL-32). IL-32 mRNA levels in primary adherent cells from patients with MDS are 14- to 17-fold higher than in controls. In contrast, cells from patients with chronic myelomonocytic leukemia (CMML), a myeloproliferative disorder with low TNFα levels, express IL-32 at only 1/10 the level observed in controls. Damage in the microenvironment may occur secondary to oxidative stress, which may also lead to accelerated shortening of telomeres. This is, indeed, true for hematopoietic cells in MDS marrow, but telomere length in marrow stroma does not differ from that in age-matched healthy individuals. Nevertheless, the stroma shows functional aberrancies. Stroma-derived signals facilitate apoptosis in clonal hematopoietic cells but not in normal CD34+ cells. Thus while stroma dysfunction is likely due to signals derived from the hematopoietic clone rather than being intrinsic, it does affect clonal death or survival, respectively. Therefore, signals exchanged between both compartments could serve as targets for therapeutic interventions.

Entities:  

Year:  2009        PMID: 20305828      PMCID: PMC2840261          DOI: 10.2174/157339409789712681

Source DB:  PubMed          Journal:  Curr Cancer Ther Rev        ISSN: 1573-3947


  43 in total

Review 1.  Stromal abnormalities in neoplastic bone marrow diseases.

Authors:  U Dührsen; D K Hossfeld
Journal:  Ann Hematol       Date:  1996-08       Impact factor: 3.673

2.  Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells.

Authors:  K Hattori; B Heissig; K Tashiro; T Honjo; M Tateno; J H Shieh; N R Hackett; M S Quitoriano; R G Crystal; S Rafii; M A Moore
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

3.  Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.

Authors:  G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

Review 4.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

5.  A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome.

Authors:  G M Gersuk; C Beckham; M R Loken; P Kiener; J E Anderson; A Farrand; A B Troutt; J A Ledbetter; H J Deeg
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

6.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.

Authors:  M Konopleva; S Konoplev; W Hu; A Y Zaritskey; B V Afanasiev; M Andreeff
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

7.  Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group.

Authors:  S R McCann; A Bacigalupo; E Gluckman; W Hinterberger; J Hows; P Ljungman; P Marin; C Nissen; E van't Veer Kerthof; A Raghavachar
Journal:  Bone Marrow Transplant       Date:  1994-03       Impact factor: 5.483

8.  Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes.

Authors:  S D Mundle; P Venugopal; J D Cartlidge; D V Pandav; L Broady-Robinson; S Gezer; E L Robin; S R Rifkin; M Klein; D E Alston; B M Hernandez; D Rosi; S Alvi; V T Shetty; S A Gregory; A Raza
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

9.  Stromal cells in long-term murine bone marrow culture: FACS studies and origin of stromal cells in radiation chimeras.

Authors:  J E Lennon; H S Micklem
Journal:  Exp Hematol       Date:  1986-05       Impact factor: 3.084

10.  Recurrent graft failure following syngeneic bone marrow transplantation for aplastic anaemia.

Authors:  J C Marsh; N Harhalakis; C Dowding; M Laffan; E C Gordon-Smith; J M Hows
Journal:  Bone Marrow Transplant       Date:  1989-09       Impact factor: 5.483

View more
  6 in total

1.  Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate.

Authors:  Johanna Zannoni; Natacha Mauz; Landry Seyve; Mathieu Meunier; Karin Pernet-Gallay; Julie Brault; Claire Jouzier; David Laurin; Mylène Pezet; Martine Pernollet; Jean-Yves Cahn; Fabrice Cognasse; Benoît Polack; Sophie Park
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

3.  Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.

Authors:  Fernanda Marconi Roversi; Matheus Rodrigues Lopes; João Agostinho Machado-Neto; Ana Leda F Longhini; Adriana da Silva Santos Duarte; Mariana Ozello Baratti; Bruna Palodetto; Flávia Adolfo Corrocher; Fernando Vieira Pericole; Paula de Melo Campos; Patricia Favaro; Fabiola Traina; Sara Teresinha Olalla Saad
Journal:  Stem Cells Dev       Date:  2014-02-18       Impact factor: 3.272

4.  Abnormal telomere shortening of peripheral blood mononuclear cells and granulocytes in patients with chronic idiopathic neutropenia.

Authors:  Konstantia I Pavlaki; Maria-Christina Kastrinaki; Michail Klontzas; Maria Velegraki; Irene Mavroudi; Helen A Papadaki
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

Review 5.  Bone Marrow Immunity and Myelodysplasia.

Authors:  Claude Lambert; Yuenv Wu; Carmen Aanei
Journal:  Front Oncol       Date:  2016-07-20       Impact factor: 6.244

6.  De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.

Authors:  Matheus Rodrigues Lopes; João Kleber Novais Pereira; Paula de Melo Campos; João Agostinho Machado-Neto; Fabiola Traina; Sara T Olalla Saad; Patricia Favaro
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.